Covid-19 vaccine: costs, pricing and management
DOI:
https://doi.org/10.56563/costosygestion.101.3Keywords:
COVID-19, Vaccine, Manufacturing, Costs, PricesAbstract
While there is not either cure or effective treatment against COVID-19, vaccines arise as only viable option for
the world to come back to “normalcy”. Process of research & development, manufacturing and distribution of
COVID-19 vaccine is highly complex. More than 150 vaccine candidates are now being developed through different
and indeed revolutionary technologies for having vaccines available by the end of 2020 or early 2021. Objective of this paper is to present a holistic assessment of management, costs and pricing for the
COVID-19 vaccine process, studying its whole value chain, including R&D, manufacturing, marketing and
distribution, but focusing on costing techniques and methodologies used by companies, always based on
their manufacturing models and technologies. Our goal is to make contributions that could be useful for
companies and governments on three main aspects: unit cost calculation introducing life-cycle costing approach,
effective pricing decisions by pharmaceutical companies and efficient purchasing models implementation
by governments.
Scientific and technological challenge is huge. From management perspective, decision making process and
excellence in execution are key; demand for a collaborative and coordinated actions by all stakeholders is vital
to reach the goal of having an effective and safe vaccine that is widely accessed by everybody.
Downloads
References
Ansede, M. y Galocha, A. (2020). La vacuna. El único camino de regreso a la vida anterior. El País de España. Recuperado de: htpp//: elpais.com
Coronel Troncoso, G. (2001). El costo del ciclo de vida de los productos. La contabilidad basada en clientes y la contabilidad de gestión. Revista Costos y Gestión, 39.
De Ambrosio, M. (2020). Por qué es clave la fase III y otros interrogantes sobre la vacuna, La Nación. Recuperado de: https://www.lanacion.com.ar
Robinson J. M. (2016). Vaccine production: main steps and considerations. In: Bloom B. y Lambert P. H. (eds.), The vaccine book (2nd ed.). Cambridge: Academic Press.
Rodríguez, M. (2020) Vacuna contra COVID-19. ¿En qué consiste la fase 3 de ensayos clínicos y porqué es tan crucial? BBC News. Recuperado de htpp//: bbc.com
Sterin Prync, A. (2020). Vacunas para SARS-CoV-2, diferentes estrategias de los desarrollos en curso. Revista del Hospital Italiano de Buenos Aires, 40, 1, 1-13.
Understanding vaccines. National Institute of Allergy and Infectious Diseases. Recuperado de http//: www.niaid.nih.gov/topics/vaccines
Wu, K. (2020). Some vaccine makers say they plan to profit from coronavirus vaccine, New York Times. Recuperado de. https://www.nytimes.com
Zimmer, C. (2020). Inside Johnson & Johnsonʼs nonstop hunt for a coronavirus vaccine, New York Times. Recuperado de: https://www.nytimes.com
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Alejandro Smolje
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors who publish in this journal agree to the following terms:
1. The authors retain copyright and guarantee to the journal the right to be the first to publish the work as well as licensed under a Creative Commons Attribution-NonCommercial 4.0 International license. CC BY-NC 4.0.
2. Authors may separately enter into additional agreements for non-exclusive distribution of the version of the work published in the journal (e.g., placing it in an institutional repository or publishing it in a book) with an acknowledgment of its initial publication in this journal.
3. Authors are allowed and encouraged to disseminate their work electronically (e.g., in institutional repositories or on their own website) before and during the submission process, as this can lead to productive exchanges as well as earlier and greater citation of published work.
